Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019.
Anakinra
Coronavirus disease-2019
Cytokine
Tocilizumab
Journal
Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine
ISSN: 0972-5229
Titre abrégé: Indian J Crit Care Med
Pays: India
ID NLM: 101208863
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
19
07
2022
accepted:
10
08
2022
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
ppublish
Résumé
It is known that coronavirus disease-2019 (COVID-19) pneumonia causes cytokine storm, and treatment modalities are being developed on inhibition of proinflammatory cytokines. We aimed to investigate the effects of anticytokine therapy on clinical improvement and the differences between anticytokine treatments. A total of 90 patients with positive COVID-19 polymerase chain reaction (PCR) test were divided into three groups, group I ( The seventh-day mortality rates were 6.7% in group II, 23.3% in group I, and 16.7% in group III. In group II, the ferritin levels on the 7th and 14th days were significantly lower ( We observed the positive effects of the use of tocilizumab on clinical improvement in the early period; mechanical ventilation requirement was delayed and at a lower rate. Anakinra treatment did not change mortality and PaO Ozkan F, Sari S. Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019. Indian J Crit Care Med 2022;26(10):1091-1098.
Sections du résumé
Background
UNASSIGNED
It is known that coronavirus disease-2019 (COVID-19) pneumonia causes cytokine storm, and treatment modalities are being developed on inhibition of proinflammatory cytokines. We aimed to investigate the effects of anticytokine therapy on clinical improvement and the differences between anticytokine treatments.
Materials and methods
UNASSIGNED
A total of 90 patients with positive COVID-19 polymerase chain reaction (PCR) test were divided into three groups, group I (
Results
UNASSIGNED
The seventh-day mortality rates were 6.7% in group II, 23.3% in group I, and 16.7% in group III. In group II, the ferritin levels on the 7th and 14th days were significantly lower (
Conclusion
UNASSIGNED
We observed the positive effects of the use of tocilizumab on clinical improvement in the early period; mechanical ventilation requirement was delayed and at a lower rate. Anakinra treatment did not change mortality and PaO
How to cite this article
UNASSIGNED
Ozkan F, Sari S. Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019. Indian J Crit Care Med 2022;26(10):1091-1098.
Identifiants
pubmed: 36876207
doi: 10.5005/jp-journals-10071-24320
pmc: PMC9983662
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1091-1098Informations de copyright
Copyright © 2022; Jaypee Brothers Medical Publishers (P) Ltd.
Déclaration de conflit d'intérêts
Source of support: Nil Conflict of interest: None
Références
Biomed Pharmacother. 2021 Jan;133:110825
pubmed: 33378989
Arthritis Rheumatol. 2020 Jul;72(7):1059-1063
pubmed: 32293098
J Rheumatol. 2003 Jul;30(7):1426-35
pubmed: 12858437
Crit Care Med. 1997 Jul;25(7):1115-24
pubmed: 9233735
Clin Infect Dis. 2021 Jul 15;73(2):e445-e454
pubmed: 32651997
BMJ. 2021 Jan 20;372:n84
pubmed: 33472855
J Allergy Clin Immunol. 2021 Apr;147(4):1217-1225
pubmed: 33556464
Blood. 2011 Apr 7;117(14):3720-32
pubmed: 21304099
Ann Rheum Dis. 2020 Oct;79(10):1277-1285
pubmed: 32620597
Int J Clin Pharmacol Ther. 2013 Jun;51(6):443-55
pubmed: 23547848
Neurology. 2020 Sep 22;95(12):e1754-e1759
pubmed: 32546655
Eur J Neurol. 2021 Oct;28(10):3324-3331
pubmed: 33369818
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
JAMA Intern Med. 2021 Jan 1;181(1):24-31
pubmed: 33080005
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Med Virol. 2021 Jan;93(1):35-37
pubmed: 32470146
Lancet Respir Med. 2021 Dec;9(12):1427-1438
pubmed: 34756178
J Transl Med. 2020 Oct 21;18(1):405
pubmed: 33087150
Elife. 2021 Mar 08;10:
pubmed: 33682678
Crit Care. 2021 Jan 4;25(1):2
pubmed: 33397463
J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4
pubmed: 32425269
Crit Care Clin. 2006 Apr;22(2):255-71, vi
pubmed: 16677999
N Engl J Med. 2006 Apr 20;354(16):1671-84
pubmed: 16625008
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Ann Rheum Dis. 2020 Sep;79(9):1143-1151
pubmed: 32719045
J Neuroradiol. 2022 Nov;49(6):421-427
pubmed: 34800562
Eur J Intern Med. 2020 Jun;76:43-49
pubmed: 32482597
Front Med. 2021 Jun;15(3):486-494
pubmed: 33687643
N Engl J Med. 2021 Apr 22;384(16):1503-1516
pubmed: 33631066
N Engl J Med. 2021 Jan 7;384(1):20-30
pubmed: 33332779
Immun Inflamm Dis. 2022 Feb;10(2):201-208
pubmed: 34762351
Lancet Rheumatol. 2020 Jun;2(6):e325-e331
pubmed: 32501454
Ann Rheum Dis. 2020 Jul 31;:
pubmed: 32737105